Trial reportNature communications2024
Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease.
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05083806 (Multispectral Optoacoustic Tomography for Translational Molecular Imaging in Pompe Disease), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multispectral Optoacoustic Tomography for Translational Molecular Imaging in Pompe Disease
Who cites it
13 citing papers in PubMed.
- OpenQPAIData: Measurements of test objects with reference labels for quantitative photoacoustic imaging research.Scientific data · 2026Article
- Data-driven super-resolution optoacoustic imaging via physically encoded signal acquisition.Research square · 2026Article
- Longitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Optoacoustic muscle imaging.Journal of neuromuscular diseases · 2026Review
- Non-invasive biomarkers for diagnosis and monitoring of primary mitochondrial diseases.Journal of neurology · 2026Review
- Article
- An Ultra-Low-Cost Optoacoustic Method for Imaging Specific Biological Structures.Diagnostics (Basel, Switzerland) · 2026Article
- Optical and Photoacoustic Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Emergent technologies in clinical neurophysiology to study the neuromuscular system: IFCN handbook chapter.Clinical neurophysiology practice · 2026Review
- Multispectral optoacoustic tomography of salivary glands in patients with clinically suspected Sjögren's disease: A pilot study.Photoacoustics · 2025Article
- Artifacts in photoacoustic imaging: Origins and mitigations.Photoacoustics · 2025Article
- Optoacoustic imaging in lower extremity revascularization: A novel technique to assess perioperative muscle perfusion.Photoacoustics · 2025Article
- Derivation and validation of a non-invasive optoacoustic imaging biomarker for detection of patients with intermittent claudication.Communications medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pompe disease (PD) is a rare autosomal recessive glycogen storage disorder that causes proximal muscle weakness and loss of respiratory function. While enzyme replacement therapy (ERT) is the only effective treatment, biomarkers for disease monitoring are scarce. Following ex vivo biomarker validation in phantom studies, we apply multispectral optoacoustic tomography (MSOT), a laser- and ultrasound-based non-invasive imaging approach, in a clinical trial (NCT05083806) to image the biceps muscles of 10 late-onset PD (LOPD) patients and 10 matched healthy controls. MSOT is compared with muscle magnetic resonance imaging (MRI), ultrasound, spirometry, muscle testing and quality of life scores. Next, results are validated in an independent LOPD patient cohort from a second clinical site. Our study demonstrates that MSOT enables imaging of subcellular disease pathology with increases in glycogen/water, collagen and lipid signals, providing higher sensitivity in detecting muscle degeneration than current methods. This translational approach suggests implementation in the complex care of these rare disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.